Our meta-analysis showed a significant association between HER-2 overexpression and survival in osteosarcoma, which indicated that HER-2 status should be evaluated as a prognostic marker and therapeutic target for osteosarcoma. This evidence concerns the gene ERBB2 and osteosarcoma.